By Seoul, South Korea, Jan 20, 2014
HanAll BioPharma Co., Ltd announced that HanAll presented at the Biotech Showcase™ 2014
Conference held in San Francisco, CA.
Details of HanAll BioPharma Co., Ltd's presentation are as follows:
Event: | Biotech Showcase™ 2014 Conference |
Date: | Jan 13, 2014 |
Time: | 17:00 |
Location: | Parc 55 Wyndham San Francisco Union Square Hotel |
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its sixth year, Biotech Showcase is expected to attract upwards of
1,500 attendees.
HanAll BioPharma Co., Ltd is a leading R&D oriented biopharmaceutical company listed on the
Korean Stock Exchange. It has been developing innovative and unique biologics and NCE
pipelines to treat various diseases for the global market;
(1) HL176, 177 Oncology Program Targeting Cancer Metabolism
H176 and HL177, a new series of anti-cancer agents targeting cancer metabolism. The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors, including sustaining proliferative signaling, enabling replicative immortality, resisting cell death, evading growth suppressors, inducing angiogenesis, and activating invasion and metastasis. Furthermore, during the past few years two emerging hallmarks have been added
to the list which includes reprogramming of energy metabolism and evading immune destruction. It is generally recognized that most cells exhibit plasticity in their ability to generate ATP from either glycolysis or oxidative phosphorylation, whereby blockage of one metabolic pathway rapidly shifts cells to produce ATP from the other. For instance, the blockage of MCT1 and
MCT4 in cancer cell resulted in reduced rates of glycolysis with a concomitant reactivation of oxidative phosphorylation. Thus, dual treatment of blocking both glycolysis and oxidative phosphorylation has induced rapid collapse in ATP level and total cell death. HL176 and HL177, blocking oxidative phosphorylation, may be used with MCT inhibitors and/or LDH inhibitors to inhibit glycolysis and mitochondrial complex I, inducing rapid collapse in ATP level and total
cell death - a phenomenon known as the 'metabolic knife'. HanAll's HL176 and HL177 are superior compared to phenformin, a biguanide which inhibits oxidative phosphorylation, since HL176 and HL177 demonstrate greater potency when concurrently treated with glycolysis inhibitors - exhibiting greater synergistic potency. Furthermore, HL176 and HL177 have greater bioavailability and better distribution profile compared to phenformin. Thus, HanAll is currently developing HL176 and HL177 as a combination therapy and these two projects are at a
discovery stage.
(2) HL161 Fully human anti-hFcRn monoclonal antibody for autoimmune diseases
HanAll is currently developing fully human monoclonal antibodies targeting the Fc Neonatal Receptor (FcRn) for the treatment of autoimmune diseases caused by pathogenic autoantibodies(the HL 161 program).
FcRn plays essential roles in regulating serum IgG level, and humoral and cellular immunity against auto-antigen. Through blocking FcRn, the catobolism of pathogenic autoantibodies increases and humoral and cellular immunity on autoantigens are reduced.
Although the cause of autoimmune diseases has not been fully elucidated, it is generally recognized that the formation of autoantibodies is a primary cause. Thus, the production of pathogenic autoantibodies underpins the pathology in various autoimmune diseases, including Systemic Lupus Erythematosus (SLE), Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic
Purpura (ITP), Pemphigus and Neuromyelitis Optica (NMO).
HanAll's anti-hFcRn mAbs reduce the level of IgG autoantibodies in circulation and humoral and cellular immunity on auto-antigen by inhibiting FcRn, leading to therapeutic efficacy in autoimmune diseases.
HanAll is conducting hIgG catabolism studies in transgenic mice expressing hFcRn and Monkey to select final clinical candidate.
(3) HL036 Topical TNF-alpha Blocker for Dry Eye Disease
HanAll BioPharma developed TNF- blocker of HL036, a molecularly engineered soluble human TNF receptor I fragment, with optimal properties for treatment of ocular surface inflammation and confirmed the efficacy in a mouse Dry Eye Disease model:
• Protein therapeutic for high selectivity/safety
• Relatively small (~19 kDa) for efficient penetration of corneal tissue by topical administration
• Molecularly engineered for high potency/efficacy
• Blocks TNF- which is upregulated in DED
• Minimize COGs by selecting a small protein expressed in E. coli
HanAll is conducting GLP-TOX studies and IND for Phase I study will be filed in 4Q, 2014.
Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life
science industry. Now going into its fifth year, Demy-Colton has developed a number of high- value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter. For more information please visit www.demy-colton.com.
EBD Group is the leading partnering firm for the global life science industry. Since 1993,
biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. For more information please visit www.ebdgroup.comor follow EBD Group on Twitter at twitter.com/ebdgroup.
HanAll BioPharma enquiries:
Korea (HQ): US Office (HPI): Soonim Lee Seungtaek Oh
Director, Business Development Director, Business Development
+82 2 2204 1753 +1 301 738 3980 silee@hanall.co.kr stoh@hanall.co.kr
|
distributed by
|
